DD294255A5 - PROCESS FOR PREPARING TETRAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES - Google Patents

PROCESS FOR PREPARING TETRAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES Download PDF

Info

Publication number
DD294255A5
DD294255A5 DD34061090A DD34061090A DD294255A5 DD 294255 A5 DD294255 A5 DD 294255A5 DD 34061090 A DD34061090 A DD 34061090A DD 34061090 A DD34061090 A DD 34061090A DD 294255 A5 DD294255 A5 DD 294255A5
Authority
DD
German Democratic Republic
Prior art keywords
formula
aryl radical
phenyl
alkyl
chem
Prior art date
Application number
DD34061090A
Other languages
German (de)
Inventor
Gerhard W Fischer
Bernhard Olk
Original Assignee
Adw Forschungsstelle Fuer Chemische Toxikologie,De
Zi Fuer Isotopen- Und Strahlenforschung,De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adw Forschungsstelle Fuer Chemische Toxikologie,De, Zi Fuer Isotopen- Und Strahlenforschung,De filed Critical Adw Forschungsstelle Fuer Chemische Toxikologie,De
Priority to DD34061090A priority Critical patent/DD294255A5/en
Publication of DD294255A5 publication Critical patent/DD294255A5/en

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung beschreibt ein Verfahren zur Herstellung tetrazolylsubstituierter Pyrimidinderivate. Heterocyclen dieses Typs sind als Zwischenprodukte zur Synthese biologisch aktiver Verbindungen von Interesse. Die Titelverbindungen werden erfindungsgemaesz hergestellt, indem man * (Formel I) in Loesungsmitteln wie Acetonitril oder Benzen mit Carbonsaeurehalogeniden (Formel II) in Gegenwart aequimolarer Mengen einer Hilfsbase wie Pyridin oder Triethylamin bei Temperaturen bis zum Siedepunkt des Reaktionsgemisches umsetzt und die hierbei gebildeten * (Formel III) mit Guanidin (Formel IV, R3NH2) oder Carbonsaeureamidinen (Formel IV, R3H, Alkyl, Aryl) in siedender alkoholischer Loesung in Gegenwart eines basischen Kondensationsmittels, z. B. Natriumalkoholat, zur Reaktion bringt.{Pyrimidinderivate; * Zwischenprodukte; * Carbonsaeurehalogenide; Pyridin; Triethylamin; * Guanidin; Carbonsaeureamidine; Natriumalkoholat}The invention describes a process for the preparation of tetrazolyl-substituted pyrimidine derivatives. Heterocycles of this type are of interest as intermediates for the synthesis of biologically active compounds. The title compounds are prepared according to the invention by reacting * (formula I) in solvents such as acetonitrile or benzene with carbonyl halides (formula II) in the presence of equimolar amounts of an auxiliary base such as pyridine or triethylamine at temperatures up to the boiling point of the reaction mixture and the * (formula III) with guanidine (formula IV, R3NH2) or Carbonsaeureamidinen (formula IV, R3H, alkyl, aryl) in boiling alcoholic solution in the presence of a basic condensing agent, eg. As sodium alcoholate, brings to the reaction {Pyrimidinderivate; * Intermediates; * Carboxylic acid halides; pyridine; triethylamine; * Guanidine; Carbonsaeureamidine; sodium alcoholate}

Description

bedeuten, in Gegenwart äquimolarer Mengen einer Hilfsbase wie Pyridin oder Triethylamin bei Temperaturen bis zum Siedepunkt des Reaktionsgemisches umseut und die hierbei gebildeten 1-ary!substituierten 5-(1-Acyl-2-d!methylamino-vinyl)-1 H-tetrazole III mit Guanidin (Formel IV, R3 = NH2) oder Carbonsäureamiden (Formel IV, R3 = H, Alkyl oder Aryl) in siedender alkoholischer (z. B. methanolischer oder ethanolischer) Lösung in Gegenwart eines basischen Kondensationsmittels, z. B. Natriummethanolat oder Natriumethanolat, zur Reaktion bringt. Die Zwischenprodukte III fallen beim Einengen des Reaktionsgemisches in fester kristalliner Form zusammen mit dem Hydrohalogenid der Hilfsbase an und werden von diesem durch Waschen mit Wasser befreit. Die Reaktionskomponenten IV (R3 = NH2, H, Alkyl, Aryl) können in Form ihrer jagerstabilen Salze (z.B. Hydrosulfate, Hydrochloride u.a.) verwendet und im Reaktionsgemisch durch einen entsprechenden Überschuß ah basischem Kondensationsmittel freigesetzt werden.mean in the presence of equimolar amounts of an auxiliary base such as pyridine or triethylamine at temperatures up to the boiling point of the reaction mixture umseut and the resulting 1-ary! substituted 5- (1-acyl-2-d! methylamino-vinyl) -1H-tetrazoles III with guanidine (formula IV, R 3 = NH 2 ) or carboxylic acid amides (formula IV, R 3 = H, alkyl or aryl) in boiling alcoholic (eg methanolic or ethanolic) solution in the presence of a basic condensing agent, e.g. As sodium methoxide or sodium ethoxide, brings to the reaction. The intermediates III are obtained on concentration of the reaction mixture in solid crystalline form together with the hydrohalide of the auxiliary base and are freed from this by washing with water. The reaction components IV (R 3 = NH 2 , H, alkyl, aryl) can be used in the form of their chelator-stable salts (eg hydrosulfates, hydrochlorides, etc.) and released in the reaction mixture by a corresponding excess ah basic condensing agent.

Die Ausgangsverbindungen I sind durch Umsetzung von 3-Halogen-prop-2-en-1-ylidendimethyliminiumsalzen mit überschüssigem Natriumazid in alkoholischer Lösung leicht zugänglich (DD 268690; vgl. G.W. FISCHER und M. HERRMANN, J. prakt. Chem. 330 [1988] 963).The starting compounds I are readily accessible by reaction of 3-halo-prop-2-en-1-ylidenedimethyliminium salts with excess sodium azide in alcoholic solution (DD 268690, compare GW FISCHER and M. HERRMANN, J. prakt. Chem ] 963).

Die Erfindung wird nachstehend an 8 Ausführungsbetspielen erläutort; die hierin angegebenen Ausbeuten an V beziehen sich auf die eingesetzten 1-Aryl-5-(2-dlmethylamino-vinyl)-1 H-tetrazole I.The invention will be explained below with reference to 8 embodiments; the yields of V given herein are based on the 1-aryl-5- (2-dimethylamino-vinyl) -1H-tetrazoles I.

Ausführungsbeispieleembodiments Beispiel 1example 1

2-Amino-4-methyl-5-(1-phenyl-1H-tetrazol-5-yl)-pyrimidin (V, R1 = Ph, R7 = Me,R3 = NH2)2-amino-4-methyl-5- (1-phenyl-1H-tetrazol-5-yl) -pyrimidine (V, R 1 = Ph, R 7 = Me, R 3 = NH 2 )

Eine heiße Lösung von 2,15g (10mmol) 5-(2-Dimethylamino-vinyl)-1 -phenyl-1 H-tetrazol (I, R1 = Ph) in 5ml absol. Acetonitril undA hot solution of 2.15 g (10 mmol) of 5- (2-dimethylamino-vinyl) -1-phenyl-1H-tetrazole (I, R 1 = Ph) in 5 ml of absolute. Acetonitrile and

0,95g (12mmol) trockenem Pyridin wird mit 0,94g (12mmol) Acetylchlorid (II, R2 = Me, X = Cl) versetzt und unter0.95 g (12 mmol) of dry pyridine is mixed with 0.94 g (12 mmol) of acetyl chloride (II, R 2 = Me, X = Cl) and under

Feuchtigkeitsausschluß 2,5 Std. bei 80°C auf dem Wasserbad erhitzt. Anschließend zieht man das Lösungsmittel i. Vak. ab,Exclusion of moisture 2.5 h. At 80 ° C heated on a water bath. Then you draw the solvent i. Vak. from,

digeriert den verbleibenden Rückstand mit Wasser, saugt ab, wäscht mit Wasser und trocknet über PjO6. Das so erhaltenedigested the remaining residue with water, filtered off with suction, washed with water and dried over PjO 6 . The thus obtained

Zwischenprodukt III, R1 = Ph, R2 = Me wird zusammen mit 2,25g (lOmmol) Guanidinsulfat (2IV · H2SO4 · 0,5 H2O, R3 = NH2) inIntermediate III, R 1 = Ph, R 2 = Me, together with 2.25 g (10 mmol) of guanidine sulfate (2IV.H 2 SO 4 .0.5 H 2 O, R 3 = NH 2 )

20 ml einer 1N ethanolischen Natriumethanolatlösung 3 Std. unter magnetischem Rühren rückfließend erhitzt, wobei sich das20 ml of a 1N ethanolic sodium ethanolate refluxing 3 hr. With magnetic stirring, the

Reaktionsprodukt bereits aus der heißen Lösung abzuscheiden beginnt. Nach dem Abkühlen saugt man ab, wäscht mit wenigReaction product already begins to precipitate from the hot solution. After cooling, filtered off with suction, washed with a little Ethanol, dann mehrmals mit Wasser und trocknet über P2O6. Ausbeute 1,87g (54%); farblose Kristalle (aus Acetonitril), Schmp.Ethanol, then several times with water and dried over P 2 O 6 . Yield 1.87g (54%); colorless crystals (from acetonitrile), m.p. Analog werden erhalten:Analog receive:

2-Amino-4-methyl-5-[1-(4-methyl-phenyl)-1H-tetrazol-5-yl]-pyrimidin (V, R1 = 4-Me-C6H4, R2 = Me, R3 = NH2) Ausbeute 83%. Farblose Kristalle (aus Acetonitril), Schmp. 225-2260C.2-Amino-4-methyl-5- [1- (4-methyl-phenyl) -1H-tetrazol-5-yl] -pyrimidine (V, R 1 = 4-Me-C 6 H 4 , R 2 = Me , R 3 = NH 2 ) Yield 83%. Colorless crystals (from acetonitrile), mp. 225-226 0 C.

2-Amino-5-[1-(4-ethyl-phenyl)-1H-tetrazol-5-yl)-4-methyl-pyrimidin (V, R1 = 4-Et-CeH4, R2 = Me, R3 = NH2) Ausbeute 75%. Farblose Blättchen (aus Ethanol), Schmp. 197-1980C.2-Amino-5- [1- (4-ethyl-phenyl) -1H-tetrazol-5-yl) -4-methylpyrimidine (V, R 1 = 4-Et-C e H 4 , R 2 = Me , R 3 = NH 2 ) Yield 75%. Colorless platelets (from ethanol), mp 197-198 0 C.

2-Amino-6-H-(4-methoxy-phenyl)-1 H-tetrazol-5-yl]-4-methyl-pyrim!din (V, R1 = 4-MeO-C„H4, R2 = Me, R3 = NH2) Ausbeute 89%. Farblose Kristalle (aus Ethanol), Schmp. 193-1940C.2-Amino-6-H- (4-methoxyphenyl) -1H-tetrazol-5-yl] -4-methyl-pyrimidine (V, R 1 = 4-MeO-C "H 4 , R 2 = Me, R 3 = NH 2 ) Yield 89%. Colorless crystals (from ethanol), mp 193-194 0 C.

2-Amino-5-I1-(4-fluor-phenyl)-1H-tetrazol·5-yl]-4-methyl-pyrimidln (V, R1 = 4-F-CeH4, R2 = Me, R3 = NH2) Ausbeute 79%. Farblose Blättchen (aus Acetonitril), Schmp. 225-2260C.2-Amino-5-I1- (4-fluoro-phenyl) -1H-tetrazol-5-yl] -4-methyl-pyrimidine (V, R 1 = 4-FC e H 4 , R 2 = Me, R 3 = NH 2 ) yield 79%. Colorless flake (from acetonitrile), mp. 225-226 0 C.

2-Amino-5-[1-(4-chlor-phenyl)-1H-tetrazol-5-yll-4-methyl-pyrimidin (V, R1 = 4-CI-CeH4, R2 = Me, R3 = NH2) Ausbeute 77%. Farblose Blättchen (aus Acetonitril), Schmp. 251-2520C (Zers.).2-Amino-5- [1- (4-chloro-phenyl) -1H-tetrazol-5-yl-4-methylpyrimidine (V, R 1 = 4-Cl-CeH 4 , R 2 = Me, R 3 = NH 2 ) yield 77%. Colorless leaves (from acetonitrile), mp 251-252 0 C (dec.).

2-Amino-5-[1-(4-brom-phenyl)-1H-tetrazol-5-yll-4-methyl-pyrimidin (V, R1 = 4-Br-C8H4, R2 = Me, R3 = NH2) Ausbeute 83%. Farblose Blättchen (aus Dioxan), Schmp. 257-2580C (Zers.)2-amino-5- [1- (4-bromo-phenyl) -1H-tetrazol-5-yl-4-methylpyrimidine (V, R 1 = 4-Br-C 8 H 4 , R 2 = Me, R 3 = NH 2 ) Yield 83%. Colorless Leaflets (made of Dioxane), m.p. 257-258 0 C (Zers.)

2-Amino-5-(1-(4-iod-phenyl)-1H-tetrazol-5-yl|-4-methyl-pyrimldin (V, R' = 4^C4H4, R2 = Me, R3 = NH2) Ausbeute 86%. Farblose Blättchen (aus Dioxan), Schmp. 256-2570C (Zers.).2-Amino-5- (1- (4-iodo-phenyl) -1H-tetrazol-5-yl-4-methyl-pyrimidine (V, R '= 4 C 4 H 4 , R 2 = Me, R 3 = NH 2 ) Yield 86% Colorless flakes (from dioxane), mp 256-257 0 C (dec.).

2.Amlno-5-l1-(4-biphenylyl)-1H-tetrazol-5-yll-4-methyl-pyrimidln (V, R1 - 4-Ph-C9H4, R2 = Me, R3 = NH2) Ausbeute 70%. Farblose Kristalle (aus Dioxan), Schmp. 222-2230C2. Amlno-5-l1- (4-biphenylyl) -1H-tetrazol-5-yl-4-methyl-pyrimidine (V, R 1 -4-Ph-C 9 H 4 , R 2 = Me, R 3 = NH 2 ) yield 70%. Colorless crystals (from dioxane), mp 222-223 0 C

2-Amlno-4-ethyl-5-(1-phenyl-1H-tetrazol-5-yl)-pyrimldln (V, R1 = Ph, R2 = Et, R3 = NH2) Ausbeute 81 %. Farblose Kristalle (aus Methanol), Schmp. 170-1710C.2-Amino-4-ethyl-5- (1-phenyl-1H-tetrazol-5-yl) pyrimidine (V, R 1 = Ph, R 2 = Et, R 3 = NH 2 ) Yield 81%. Colorless crystals (from methanol); mp. 170-171 0 C.

2-Amino-2-ethyl-5-|1-(4-methyl-phenyl)-1H-tetrazol-5-yl)-pyrimldin (V, R* = 4-Me-CgH4, R2 = Et, R3 = NH2) Ausbeute 90%. Farblose Kristalle (aus Methanol), Schmp. 157-1580C2-Amino-2-ethyl-5- | 1- (4-methylphenyl) -1H-tetrazol-5-yl) -pyrimidine (V, R * = 4-Me-CgH 4 , R 2 = Et, R 3 = NH 2 ) Yield 90%. Colorless crystals (from methanol), mp 157-158 0 C

2-ΑΓηίηο-5-(1-ρηβηγΜΗ·ΙβΐΓ8ζοΙ-5-γΙ)·4·ρΓοργΙ·ρνΓίπιΙα1η (V, R1 - Ph, R2 = Pr11R3 = NH2) Ausbeute 88%. Farblose Kristalle (aus Methanol), Schmp. 132-1330C.2-ΑΓηίηο-5- (1-ρηβηγΜΗ · ΙβΐΓ8ζοΙ-5-γΙ) · 4 · ρΓοργΙ · ρνΓίπιΙα1η (V, R 1 - Ph, R 2 = Pr 11 R 3 = NH 2 ) Yield 88%. Colorless crystals (from methanol); mp. 132-133 0 C.

2^Ιηο-5-[1-(4^βΙηνΙ·ρηβηνΙ)-1Η-ΙβΐΓβζοΙ·5-νΙ)-4-ρΓθρνΙ-ρνΜπ^Ιη (V, R1 = 4-Me-C,H4, R2 = Pr, R3 = NH2) Ausbeute 86%. Farblose Kristalle (aus Methanol), Schmp. 180-1810C.2 ^ Ιηο-5- [1- (4ββΙηνΙ · ρηβηνΙ) -1Η-ΙβΐΓβζοΙ · 5-νΙ) -4-ρΓθρνΙ-ρνΜπ ^ Ιη (V, R 1 = 4-Me-C, H 4 , R 2 = Pr, R 3 = NH 2 ) yield 86%. Colorless crystals (from methanol); mp. 180-181 0 C.

Beispiel 2Example 2

2-Amino-4-phenyl-5-(1-phenyM H-tetrazol-5-yl)-pyrimldin (V, R1 = R2 = Ph, R3 = NH2)2-amino-4-phenyl-5- (1-phenyl-H-tetrazol-5-yl) -pyrimidine (V, R 1 = R 2 = Ph, R 3 = NH 2 )

2,15g (lOmmol) 5-(2-Dlmethylamino-vlnyl)-1 -phenyl-1 H-tetrazol (I, R' = Ph) werden in 10ml absol. Benzen mit 1,21 g (12mmol)2.15 g (10 mmol) of 5- (2-dimethylaminophenyl) -1-phenyl-1H-tetrazole (I, R '= Ph) are dissolved in 10 ml of absolute. Benzen with 1.21 g (12mmol)

wasserfreiem Triethylamin und 1,69g (12mmol) Benzoylchlorid (II, R2 = Ph, X = Cl) 4 Std. unter Feuchtigkeitsausschluß rückfließend erhitzt. Anschließend destilliert man die reichliche Hälfte des Lösungsmittels I. Vak. ab und läßt in der Kälte kristallisieren. Das Kristallgemisch wird abgesaugt, durch Waschen mit Wasser von Triethylaminhydrochlorid befreit und getrocknet. Das so erhaltene Zwischenprodukt III (R' = R2 = Ph) wird zusammen mit 2,25g (lOmmol) Guanidinsulfat (2IV · H2SO4 · 0,5 H2O, R3 = NH2) in 20 ml einer 1N methanolischen Natriummethanolatlösung 4 Std. unter magnetischemanhydrous triethylamine and 1.69 g (12 mmol) of benzoyl chloride (II, R 2 = Ph, X = Cl) refluxing for 4 hours with exclusion of moisture. Then distilled the plentiful half of the solvent I. Vak. and lets crystallize in the cold. The crystal mixture is filtered off with suction, freed from triethylamine hydrochloride by washing with water and dried. The resulting intermediate III (R '= R 2 = Ph) is combined with 2.25 g (10 mmol) guanidine sulfate (2IV.H 2 SO 4 .0.5 H 2 O, R 3 = NH 2 ) in 20 ml of 1N methanolic sodium methoxide solution 4 hours under magnetic

Rühren rückfließend erhitzt. Nach dem Abkühlen wird abgesaugt, zunächst mit Methanol, dann mehrmals mit WasserStirring refluxed. After cooling, the product is filtered off with suction, first with methanol, then several times with water

gewaschen und getrocknet. Ausbeute 2,50g (79%); farblose Blättchen (aus Dioxan), Schmp. 267-2680C (Zers.).washed and dried. Yield 2.50 g (79%); colorless platelets (made of dioxane), mp 267-268 0 C (Zers.).

Beispiel 3Example 3

2-Amino-5-H-(4-methyl-phenyl)-1H-tetrazol-5-yl]-4-phenyl-pyrimidin (V, R1 = 4-Me-C8H4, R2 = Ph, R3« NH2)2-amino-5-H- (4-methylphenyl) -1H-tetrazol-5-yl] -4-phenyl-pyrimidine (V, R 1 = 4-Me-C 8 H 4 , R 2 = Ph, R 3 «NH 2 )

Eine heiße Lösung von 2,29g (lOmmol) 5-(2-Dimethylamino-vinyl)-1-(4-methyl-phonyl)-1H-tetrazol (I, R' = 4-Me-C6H4) in 5mlA hot solution of 2.29 g (lOmmol) of 5- (2-dimethylamino-vinyl) -1- (4-methyl-phonyl) -1H-tetrazole (I, R '= 4-Me-C 6 H 4) in 5ml

absol. Acetonitril und 0,95g (12mmol) trockenem Pyridin wird mit 1,69g (12mmol) Benzoylchlorid (II, R2 = Ph, X = Cl) versetzt und unter Feuchtigkeitsausschluß 3 Std. bei 8O0C auf dem Wasserbad erhitzt. Danach zieht man das Lösungsmittel i. Vak. ab, digeriert den Rückstand mit kaltem Wasser, saugt ab, wäscht mit Wasser und trocknet über P2Oe. Das so erhalteneabsol. Acetonitrile and 0.95 g (12 mmol) of dry pyridine is treated with 1.69 g (12 mmol) of benzoyl chloride (II, R 2 = Ph, X = Cl) and heated with exclusion of moisture for 3 hrs. At 8O 0 C on a water bath. Then draw the solvent i. Vak. The residue is digested with cold water, filtered off, washed with water and dried over P 2 Oe. The thus obtained

Zwischenprodukt III, R1 = 4-Me-CeH4, R2 - Ph wird zusammen mit 2,25g (lOmmol) Guanidinsulfat (2IV · H2SO4 · 0,5 H2O, R3 =Intermediate III, R 1 = 4-Me-C e H 4 , R 2 -Ph is used together with 2.25 g (10 mmol) of guanidine sulfate (2IV.H 2 SO 4 .0.5 H 2 O, R 3 = NH2) in 20 ml einer 1N ethanolischen Natriumethanolatlösung 3 Std. unter magnetischem Rühren rückfließend erhitzt, wobei dasNH 2 ) in 20 ml of a 1N ethanolic sodium ethanolate solution refluxing for 3 hours with magnetic stirring, the

erstere langsam in Lösung geht und sich gleichzeitig das Endprodukt abzuscheiden beginnt. Nach dem Abkühlen saugt man ab, wäscht zuerst mit Ethanol, dann mehrmals mit Wasser und trocknet Ober P2O6. Ausbeute 2,88g (87%); farblose Blättchen (ausThe former slowly dissolves and at the same time the final product begins to separate. After cooling, the solution is filtered off with suction, washed first with ethanol, then several times with water and dried over P 2 O 6 . Yield 2.88g (87%); colorless leaves (out

Dioxan), Schmp. 269-27O0C.Dioxane), mp. 269-27O 0 C. Analog werden erhalten:Analog receive:

2-Amino-5-l1-(4-ethyl-phenyl)-1H-tetrazol-5-yll-4-phenyl-pyrimidin (V, R1 = 4-Et-C6H4, R2 = Ph, R3 = NH2) Ausbeute 85%. Farblose Kristalle (aus Dioxan), Schmp. 244-2450C.2-Amino-5-l1- (4-ethyl-phenyl) -1H-tetrazol-5-yl-4-phenyl-pyrimidine (V, R 1 = 4-Et-C 6 H 4 , R 2 = Ph, R 3 = NH 2 ) yield 85%. Colorless crystals (from dioxane), mp 244-245 0 C.

2-Amino-5-[1-(4-methoxy-phenyl)-1H-tetrazol-5-yl]-4-phenyl-pyrlmidin (V, R1 = 4-MeO-C6H4, R2 = Ph, R3 = NH2) Ausbeute 75%. Farblose Blättchen (aus Dioxan), Schmp. 246-2470C.2-Amino-5- [1- (4-methoxyphenyl) -1H-tetrazol-5-yl] -4-phenyl-pyrimidine (V, R 1 = 4-MeO-C 6 H 4 , R 2 = Ph , R 3 = NH 2 ) Yield 75%. Colorless leaflets (dioxane), mp 246-247 0 C.

2-Amino-5-[1-(4-fluor-phenyl)-1H-tetrazol-5-yl]-4-phenyl-pyrimidin (V, R1 = 4-F-C6H4, R2 = Ph, R3 = NH2) Ausbeute 85%. Farblose Blättchen (aus Dioxan), Schmp. 274-2750C (Zers.).2-Amino-5- [1- (4-fluoro-phenyl) -1H-tetrazol-5-yl] -4-phenyl-pyrimidine (V, R 1 = 4-FC 6 H 4 , R 2 = Ph, R 3 = NH 2 ) yield 85%. Colorless leaflets (made of dioxane), mp 274-275 0 C (Zers.).

2-Amlno-5-(1-(4-chlor-phenyl)-1H-tetrazol-5-yll-4-phenyl-pyrimidin (V, R' = 4-CPC6H4, R2 = Ph, R3 = NH2) Ausbeute 90%. Farblose Kristalle (aus Dioxan), Schmp. 284-2850C (Zers.).2-Amino-5- (1- (4-chloro-phenyl) -1H-tetrazol-5-yl-4-phenyl-pyrimidine (V, R '= 4-CPC 6 H 4 , R 2 = Ph, R 3 = NH 2 ) Yield 90% Colorless crystals (from dioxane), mp 284-285 0 C (dec.).

2-Amino-5-|1-(4-brom-phenyl)-1H-tetrazol-5-yl]-4-phenyl-pyrimidin (V, R1 = 4-Br-C6H4, R2 = Ph, R3 = NH2) Ausbeute 84%. Farblose Blättchen (aus Dioxan), Schmp. 285-2860C (Zers.)2-Amino-5- | 1- (4-bromo-phenyl) -1H-tetrazol-5-yl] -4-phenyl-pyrimidine (V, R 1 = 4-Br-C 6 H 4 , R 2 = Ph , R 3 = NH 2 ) Yield 84%. Colorless Leaflets (made of dioxane), m.p. 285-286 0 C (Zers.)

2-Amino-5-(1-(4-iod-phenyl)-1H-tetrazol-5-yl]-4-phenyl-pyrimldin (V, R1 = 4-1-C6H4, R2 = Ph, R3 = NH2) Ausbeute 81 %. Farblose Kristalle (aus Dioxan), Schmp. 285-2860C (Zers.).2-amino-5- (1- (4-iodo-phenyl) -1H-tetrazol-5-yl] -4-phenyl-pyrimldin (V, R 1 = 4-1-C 6 H 4, R 2 = Ph , R 3 = NH 2 ) Yield 81% Colorless crystals (from dioxane), mp 285-286 0 C (dec.).

2-Amino-4-(3-fluor-phenyl)-5-(1-phenyl-1H-tetrazol-5-yl)-pyrimldln (V, R1 = Ph, R2 = 3-F-C6H4, R3 = NH2) Ausbeute 53%. Farblose Kristalle (aus Acetonitril), Schmp. 206-2070C.2-Amino-4- (3-fluoro-phenyl) -5- (1-phenyl-1H-tetrazol-5-yl) -pyrimidine (V, R 1 = Ph, R 2 = 3-FC 6 H 4 , R 3 = NH 2 ) Yield 53%. Colorless crystals (from acetonitrile), mp. 206-207 0 C.

2-Amino-4-(3-chlor-phenyl)-5-(1-phenyl-1H-tetrazol-5-yl)-pyrlmidin (V, R1 = Ph, R2 = 3-CI-C6H4, R3 = NH2) Ausbeute 82%. Farblose Kristalle (aus Acetonitril), Schmp. 208-2090C.2-Amino-4- (3-chlorophenyl) -5- (1-phenyl-1H-tetrazol-5-yl) -pyrimidine (V, R 1 = Ph, R 2 = 3-CI-C 6 H 4 , R 3 = NH 2 ) Yield 82%. Colorless crystals (from acetonitrile), mp 208-209 0 C.

2-Amino-4-(4-chlor-phenyl)-5-(1-phenyl-1H-tetrazol-5-yl)-pyrimidin (V, R1 = Ph, R2 = 4-CI-C6H4, R3 = NH2) Ausbeute 84%. Farblose Kristalle (aus Acetonitril), Schmp. 217-2180C.2-Amino-4- (4-chloro-phenyl) -5- (1-phenyl-1H-tetrazol-5-yl) -pyrimidine (V, R 1 = Ph, R 2 = 4-CI-C 6 H 4 , R 3 = NH 2 ) Yield 84%. Colorless crystals (from acetonitrile), mp. 217-218 0 C.

Beispiel 4Example 4

4-Methyl-5-(1-phenyl-1H-tetrazol-5-yl)-pyrlmidin (V, R1 = Ph, R2 = Me, R3 = H)4-methyl-5- (1-phenyl-1H-tetrazol-5-yl) -pyrimidine (V, R 1 = Ph, R 2 = Me, R 3 = H)

2,15g (lOmmol) 5-(2-Dimethylamino-vinyl)-1-phenyl-1H-tetrazol (I, R* = Ph) werden gemäß Beispiel 1 in 5ml absol. Acetonitril und 0,95g (12 mmol) trockenem Pyridin mit 0,94 g (12 mmol) Acetylchlorid (II, R2 = Me, X = Cl) zum Zwischenprodukt III, R1 = Ph,2.15 g (10 mmol) of 5- (2-dimethylamino-vinyl) -1-phenyl-1H-tetrazole (I, R * = Ph) are obtained according to Example 1 in 5 ml of absolute. Acetonitrile and 0.95 g (12 mmol) of dry pyridine with 0.94 g (12 mmol) of acetyl chloride (II, R 2 = Me, X = Cl) to the intermediate III, R 1 = Ph,

R2 = Me umgesetzt. Letzteres erhitzt man zusammen mit 2,08g (20mmol) Formamidinacetat (IV · AcOH, R3 = H) In 20ml 1NR 2 = Me reacted. The latter is heated together with 2.08 g (20 mmol) of formamidine acetate (IV · AcOH, R 3 = H) In 20 ml of 1N

ethanoliecher Natriumethanolatlösung 3 Std. unter magnetischem Rühren am Rückfluß, destilliert dann 15 ml Ethanol ab und nimmt den Rückstand nach dem Abkühlen in Diethylether auf. Die organische Phase wird mehrmals mit Wasser gewaschen, mitEthanoliecher sodium ethanolate solution for 3 hours under magnetic stirring at reflux, then distilled off 15 ml of ethanol and the residue is taken up in diethyl ether after cooling. The organic phase is washed several times with water, with

Natriumsulfat getrocknet und eingeengt, wobei sich das Reaktionsprodukt kristallin abscheidet. Ausbeute 1,34g (56%); farbloseDried sodium sulfate and concentrated, wherein the reaction product separates crystalline. Yield 1.34g (56%); colorless Kristalle (aus Cyclohexan), Schmp. 114-1160C.Crystals (from cyclohexane), mp. 114-116 0 C. Beispiel 5Example 5

5-H-(4-Methoxy-phenyl)-1H-tetrazol-5-yl)-4-methyl-pyrimidin (V, R1 = 4-MeO-C6H4, R2 = Me, R3 = H) 2,45g (lOmmol) 1-(4-Methoxy-phenyl)-5-(2-dimothylamino-vinyl)-1H-tetrazol (I, R* = 4-MeO-C6H4) werden gemäß Beispiel 1 in 5ml ebsol. Acetonitril und 0,95g (12mmol) trockenem Pyridin mit 0,94g (12mmol) Acetylchlorid (II, R2 = Me, X = Cl) zum5-H- (4-methoxy-phenyl) -1H-tetrazol-5-yl) -4-methyl-pyrimidine (V, R 1 = 4-MeO-C 6 H 4 , R 2 = Me, R 3 = H ) 2.45 g (10 mmol) of 1- (4-methoxy-phenyl) -5- (2-dimothylamino-vinyl) -1H-tetrazole (I, R * = 4-MeO-C 6 H 4 ) are obtained in accordance with Example 1 in 5ml ebsol. Acetonitrile and 0.95 g (12 mmol) of dry pyridine with 0.94 g (12 mmol) of acetyl chloride (II, R 2 = Me, X = Cl) for

Zwischenprodukt III, R1 = 4-MeO-C6H4, R2 = Me umgesetzt. Letzteres erhitzt man zusammen mit 2,08g (20mmol)Intermediate III, R 1 = 4-MeO-C 6 H 4 , R 2 = Me reacted. The latter is heated together with 2.08g (20mmol) Formamidinacetat (IV AcOH, R3 = H) in 20 ml 1N ethanolischer Natriumethanolatlösung 3 Std. unter magnetischem Rühren amFormamidine acetate (IV AcOH, R 3 = H) in 20 ml of 1N ethanolic sodium ethoxide solution for 3 hours with magnetic stirring on Rückfluß und destilliert dann 15 ml Ethanol ab. Aus dem Rückstand scheidet sich das Reaktionsprodukt beim Abkühlen undReflux and then distilled off 15 ml of ethanol. From the residue, the reaction product separates on cooling and Anreiben, gegebenenfalls unter tropfenweiser Zugabe von etwas Wasser, kristallin ab. Man saugt ab, wäscht mehrmals mitTrituration, optionally with dropwise addition of some water, crystalline from. It sucks, washes several times Wasser und trocknet über P2O6. Ausbeute 2,34g (87%); farblose Kristalle (aus Methanol), Schmp. 143-1440C.Water and dried over P 2 O 6 . Yield 2.34g (87%); colorless crystals (from methanol), mp. 143-144 0 C. Analog werden erhalten:Analog receive:

5-(1-(4-Chlor-phenyl)-1H-tetrazol-5-yl]-4-methyl-pyrimidin (V, R1 = 4-CI-C6H4, R2 = Me, R3 = H) Ausbeute 60%. Farblose Kristalle (aus Methanol), Schmp. 133-1340C5- (1- (4-Chloro-phenyl) -1H-tetrazol-5-yl] -4-methyl-pyrimidine (V, R 1 = 4-CI-C 6 H 4 , R 2 = Me, R 3 = H) 60% yield. Colorless crystals (from methanol); mp. 133-134 0 C.

5-[1-(4-Brom-phenyl)-1H-tetrazol-5-yl)-4-methyl-pyrimldin (V, R1 = 4-Br-C6H4.. R2 - Me, R3 = H) Ausbeute 61 %. Farblose Kristalle (aus Methanol), Schmp. 153-1540C5- [1- (4-Bromo-phenyl) -1H-tetrazol-5-yl) -4-methyl-pyrimidine (V, R 1 = 4-Br-C 6 H 4 ... R 2 -Me, R 3 = H) Yield 61%. Colorless crystals (from methanol); mp. 153-154 0 C.

5-(1-(4-lod-phenyl)-1H-tetrazol-5-yll-4-methy|.pyrimldln (V, R1 = 4-1-C6H4, R2 = Me, R3 = H) Ausbeute 58%. Farblose Kristalle (aus Benzen), Schmp. 170-1710C5- (1- (4-iodo-phenyl) -1H-tetrazol-5-yll-4-methyl-| .pyrimldln (V, R 1 = 4-1-C 6 H 4, R 2 = Me, R 3 = H) 58% yield. Colorless crystals (from benzene), mp. 170-171 0 C.

4-Phenyl-5-(1 -phenyl·! H-tetrazol-5-yl)-pyrlmfdln (V, R1 = R2 = Ph, R3 = H) Ausbeute 69%. Farblose Kristalle (aus Methanol), Schmp. 121-1220C4-phenyl-5- (1-phenyl-!H-tetrazol-5-yl) -pyrylmagnolone (V, R 1 = R 2 = Ph, R 3 = H) Yield 69%. Colorless crystals (from methanol), mp 121-122 0 C

5-[1-(4-Methyl-phenyl)-1H-tetrazol-5-yl|-4-phenyl-pyrimidin (V, R1 - 4-Me-C6H4, R2 = Ph, R3 = H) Ausbeute 56%. Farblose Nadeln (aus Methanol), Schmp. 164-1650C.5- [1- (4-methyl-phenyl) -1H-tetrazol-5-yl | -4-phenyl-pyrimidine (V, R 1-4-Me-C 6 H 4, R 2 = Ph, R 3 = H) Yield 56%. Colorless needles (from methanol), mp 164-165 0 C.

5-[1-(4-Methoxy-phenyl)-1H-tetrazol-5-yl]-4-phenyl-pyrimidJn (V, R' = 4-MeO-C6H4, R2 = Ph, R3 = H) Ausbeute 82%. Farblose Kristalle (aus Methanol), Schmp. 128-1290C.5- [1- (4-methoxy-phenyl) -1H-tetrazol-5-yl] -4-phenyl-pyrimidJn (V, R '= 4-MeO-C 6 H 4, R 2 = Ph, R 3 = H) Yield 82%. Colorless crystals (from methanol); mp. 128-129 0 C.

BeispieleExamples

2,4-Dimethyl-5-l1-(4-methyl-phenyl)-1H-tetrazol-5-yl]-pyrlmidin (V, R1 = 4-Me-C6H4, R2 = R3 = Me) 2,29g dOmmol) 5-(2-Dimethylamino-vinyl)-1-(4-methyl-phenyl)-1H-tetrazol (I, R1 = 4-Me-CjH4) werden gemäß Beispiel 1 in 5ml absol. Acetonitril und 0,95g (12mmol) trockenem Pyridin mit 0,94g (12mmol) Acetylchlorid (II, R2 = Me, X = Cl) zum2,4-dimethyl-5-l1- (4-methyl-phenyl) -1H-tetrazol-5-yl] -pyrimidine (V, R 1 = 4-Me-C 6 H 4 , R 2 = R 3 = Me ) 2.29 g dOmmol) 5- (2-dimethylamino-vinyl) -1- (4-methyl-phenyl) -1H-tetrazole (I, R 1 = 4-Me-CjH 4 ) are in accordance with Example 1 in 5ml absolute. Acetonitrile and 0.95 g (12 mmol) of dry pyridine with 0.94 g (12 mmol) of acetyl chloride (II, R 2 = Me, X = Cl) for

Zwischenprodukt III, R1= 4-Me-CgH4, R2 = Me umgesetzt. Letzteres erhitzt man zusammen mit 1,89g (20mmol)Intermediate III, R 1 = 4-Me-CgH 4 , R 2 = Me reacted. The latter is heated together with 1.89g (20mmol) Acetamidinhydrochlorid (IV · HCI, R3 = Me) in 20ml einer 1N ethanolischen Natriumethanolatlösung 3 Std. unter magnetischemAcetamidine hydrochloride (IV · HCl, R 3 = Me) ethanol in 20 ml of a 1N sodium ethoxide solution for 3 h., With magnetic Rühren am Rückfluß. Nach Abdestillation von 15ml Ethanol nimmt man den erkalteten Rückstand in Diethylether auswäscht dieStirring at reflux. After distilling off 15 ml of ethanol, take the cooled residue in diethyl ether washes the

organische Phase mehrmals mit Wasser, trocknet mit Natriumsulfat und engt ein, wobei das Reaktionsprodukt langsam auskristallisiert. Ausbeute 1,82g (68%); farblose Kristalle (aus Diethylether), Schmp. 111-112°C.organic phase several times with water, dried with sodium sulfate and concentrated, the reaction product slowly crystallized. Yield 1.82g (68%); colorless crystals (from diethyl ether), mp. 111-112 ° C.

Beispiel 7Example 7

5-[H4-Chlor-phenyl)-1 H-tetrazol-5-yl]-2,4-dimethyl-pyrlmidin (V, R1 = 4-Cf-C8H4, R2 = R3 = Me) 2,50g dOmmol) 1-(4-Clor-phenyl)-5-(2-dimethylamino-vinyl)-1 H-tetrazol (I, R1 = 4-CI-CeH4) werden gemäß Beispiel 1 in 5ml absol. Acetonitril und 0,95g (12mmol) trockenem Pyridin mit 0,94g (12mmol) Acetylchlorid (II, R2 = Me,X = Cl) zum5- [H 4 -chlorophenyl] -1 H -tetrazol-5-yl] -2,4-dimethyl-pyrimidine (V, R 1 = 4-Cf-C 8 H 4 , R 2 = R 3 = Me) 2.50 g dOmmol) 1- (4-chlorophenyl) -5- (2-dimethylamino-vinyl) -1 H-tetrazole (I, R 1 = 4-CI-CeH 4 ) are in accordance with Example 1 in 5ml absol. Acetonitrile and 0.95 g (12 mmol) of dry pyridine with 0.94 g (12 mmol) of acetyl chloride (II, R 2 = Me, X = Cl) for

Zwischenprodukt III, R' = 4-ChC6H4, R2 = Me umgesetzt. Letzteres erhitzt man zusammen mit 1,89 g (20 mmol)Intermediate III, R '= 4-ChC 6 H 4 , R 2 = Me reacted. The latter is heated together with 1.89 g (20 mmol) Acetamidinhydrochlorid (IV · HCI, R3 = Me) in 20 ml 1N ethanolischer Natriumethanolatlösung 3 Std. unter magnetischemAcetamidine hydrochloride (IV · HCl, R 3 = Me) in 20 ml of 1N ethanolic sodium ethoxide solution for 3 hours under magnetic Rühren am Rückfluß und destilliert dann 15ml Ethanol ab. Das sich beim Abkühlen und Anreiben bildende Kristallisat wirdStirring at reflux and then distilled off 15 ml of ethanol. The formed during cooling and grinding crystals

abgesaugt, zuerst mit wenig Ethanol, dann mehrmals mit Wasser gewaschen und getrocknet. Ausbeute 2,06g (72%); farblosefiltered off with suction, washed first with a little ethanol, then several times with water and dried. Yield 2.06 g (72%); colorless

Kristalle (aus Methanol), Schmp. 176-1770C.Crystals (from methanol), mp 176-177 0 C. Analog werden erhalten:Analog receive:

5-[1-(4-Brom-phenyl)-1 H-tetrazol-5-yl]-2,4-dimethyl-pyrlmidin (V, R1 = 4-Br-C4H4, R2 = R3 = Me)5- [1- (4-Bromo-phenyl) -1H-tetrazol-5-yl] -2,4-dimethyl-pyrimidine (V, R 1 = 4-Br-C 4 H 4 , R 2 = R 3 = Me)

Ausbeute 90%. Farblose Kristalle (aus Methanol), Schmp. 204-2050C.Yield 90%. Colorless crystals (from methanol), mp 204-205 0 C.

2-Mothyl-4-phenyl-5-(1-phenyl-1 H-tetrazol-5-yl)-pyrlmidin (V, R1 = R2 = Ph, R3 = Me)2-Mothyl-4-phenyl-5- (1-phenyl-1H-tetrazol-5-yl) -pyrimidine (V, R 1 = R 2 = Ph, R 3 = Me)

Ausbeute 82%. Farblose Kristalle (aus Methanol), Schmp. 130-131°C.Yield 82%. Colorless crystals (from methanol), mp 130-131 ° C.

2-Methyl-5'(1-(4-methyl-phenyl)-1 H-tetrazol-5-yl|-4-phenyl-pyrimidin (V, R1 = 4-Me-C8H4, R2 = Ph, R3 = Me)2-Methyl-5 '(1- (4-methyl-phenyl) -1H-tetrazol-5-yl-4-phenyl-pyrimidine (V, R 1 = 4-Me-C 8 H 4 , R 2 = ph, R 3 = Me)

Ausbeute 85%. Farblose Kristalle (aus Methanol), Schmp. 166-1670C.Yield 85%. Colorless crystals (from methanol), mp 166-167 0 C.

5-(1-(4-Methoxy-phenyl)-1 H-tetrazol-5-yl]-2-methyl-4-phenyl-pyrim!d!n (V, R1 = 4-MeO-CjH4, R2 = Ph, R3 = Me)5- (1- (4-methoxy-phenyl) -1 H-tetrazol-5-yl] -2-methyl-4-phenyl-pyrim! D! N (V, R 1 = 4-MeO-CJH 4, R 2 = Ph, R 3 = Me)

Ausbeute 62%. Farblose Kristalle (aus Methanol), Schmp. 148-1490C.Yield 62%. Colorless crystals (from methanol); mp. 148-149 0 C.

5-|1-(4-Chlor-phenyl)-1 H-tetrazol-5-yll-2-methyl-4-phenyl-pyrimldin (V, R1 = 4-CI-C8H4, R2 = Ph, R3 » Me)5- | 1- (4-chloro-phenyl) -1 H-tetrazol-5-yll-2-methyl-4-phenyl-pyrimldin (V, R 1 = 4-CI-C 8 H 4, R 2 = Ph , R 3 »Me)

Ausbeute 91 %. Farblose Nadeln (aus Methanol), Schmp. 170-1710C.Yield 91%. Colorless needles (from methanol); mp. 170-171 0 C.

5-I1-(4-Brom-phenyl)-1 H-tetrazol-5-yl]-2-methyl-4-phenyl-pyrimidin (V, R1« 4-Br-C8H4, R2 = Ph, R3 = Me)5-I1- (4-Bromo-phenyl) -1H-tetrazol-5-yl] -2-methyl-4-phenyl-pyrimidine (V, R 1 -4-Br-C 8 H 4 , R 2 = Ph , R 3 = Me)

Ausbeute 85%. Farblose Nadeln (aus Ethanol), Schmp. 186-1870C.Yield 85%. Colorless needles (made of ethanol), mp 186-187 0 C. Beispiel 8Example 8

4-Methyl-2-phenyl-5-(1-phenyM H-tetrazol-5-yl)-pyrimidin (V, R1 = R3 = Ph, R2 = Me) 2,15g dOmmol) 5-(2-Dimethylamino-vinyl)-1-phenyl-1 H-tetrazol (I, R1 = Ph) werden gemäß Beispiel 1 in 5ml absol. Acetonitril undO,95g(12mmol) trockenem Pyridin mit 0,94g(12mmol) Acetylchlorid (II, R2 = Me, X = Cl) zum Zwischenprodukt III, R1 - Ph,4-Methyl-2-phenyl-5- (1-phenyl-H-tetrazol-5-yl) -pyrimidine (V, R 1 = R 3 = Ph, R 2 = Me) 2.15g dOmmol) 5- (2- Dimethylamino-vinyl) -1-phenyl-1 H-tetrazole (I, R 1 = Ph) are in accordance with Example 1 in 5ml absol. Acetonitrile and O, 95g (12 mmol) of dry pyridine with 0.94 g (12 mmol) of acetyl chloride (II, R 2 = Me, X = Cl) to give the intermediate III, R 1 - Ph,

R2 = Me und diese analog Beispiel 7 in 20ml 1N ethanolischer Natriumethanolatlösung mit 3,13g (20mmol)R 2 = Me and these analogously to Example 7 in 20 ml of 1N ethanolic sodium ethoxide solution with 3.13 g (20 mmol) Benzamidinhydrochlorid (IV · KCI, R3 = Ph)) umgesetzt. Aus dem nach Abdestillation von 16 ml Ethanol verbleibendenBenzamidine hydrochloride (IV · KCl, R 3 = Ph)) reacted. From the remaining after distilling off 16 ml of ethanol Rückstand beginnt beim Abkühlen, tropfenweisen Wasserzusatz und Anreiben das Reaktionsprodukt auszukristallisieren,Residue begins on cooling, dropwise addition of water and rubbing the reaction product crystallize,

dessen Abscheidung durch weitere Wasserzugabe vervollständigt wird. Nach dem Absaugen, Waschen mit Wasser undwhose deposition is completed by further addition of water. After aspirating, washing with water and

Trocknen resultieren 1,77g (56%) Rohkristallisat. Umkristallisation aus Methanol liefert farblose Kristalle vom Schmp.Drying results in 1.77 g (56%) of crude crystals. Recrystallization from methanol gives colorless crystals of mp. Analog werden erhalten:Analog receive:

4-Methyl-5-[1-(4-methyl-phenyl)-1-H-tetrazol-5-yll-2-phenyl-pyrimldin (V, R1 = 4-Me-C8H4, R2 =· Me, R3 = Ph)4-Methyl-5- [1- (4-methylphenyl) -1-H-tetrazol-5-yl-2-phenyl-pyrimidine (V, R 1 = 4-Me-C 8 H 4 , R 2 = Me, R 3 = Ph)

Ausbeute 90%. Farblose Kristalle (aus Methanol), Schmp. 117-118°C.Yield 90%. Colorless crystals (from methanol), mp 117-118 ° C.

5-[1-(4-Fluor-phenyl)-1 H-tetrazol-5-yll-4-methyl-2-phenyl-pyrimidin (V, R' = 4-F-C8H4, R2 = Me, R3 = Ph)5- [1- (4-Fluoro-phenyl) -1H-tetrazol-5-yl-4-methyl-2-phenyl-pyrimidine (V, R '= 4-FC 8 H 4 , R 2 = Me, R 3 = Ph)

Ausbeute 81 %. Farblose Nadeln (aus Ethanol), Schmp. 153-1540C.Yield 81%. Colorless needles (from ethanol), mp. 153-154 0 C.

2,4-Dlphenyl-5-(1-phenyM H-tetrazol-5-yl)-pyrlmidin (V, R1 - R1 - R3 = Ph)2,4-Dlphenyl-5- (1-phenylm H-tetrazol-5-yl) -pyrlmidine (V, R 1 - R 1 - R 3 = Ph)

Ausbeute 90%; Farblose Kristalle (aus Acetonitril), Schmp. 182-1830C.Yield 90%; Colorless crystals (from acetonitrile), mp 182-183 0 C.

5-[1-(4-Methyl-phenyl)-1 H-tetrazol-5-yl]-2,4-dlphenyl-pyrimidin (V, R1 = 4-Me-C8H4, R2 = R3 = Ph)5- [1- (4-Methyl-phenyl) -1H-tetrazol-5-yl] -2,4-dl-phenyl-pyrimidine (V, R 1 = 4-Me-C 8 H 4 , R 2 = R 3 = Ph)

Ausbeute 89%. Farblose Kristalle (aus Acetonitril), Schmp. 159-1600C.Yield 89%. Colorless crystals (from acetonitrile), mp 159-160 0 C.

5-|1-(4-Ethyl-phenyl)-1 H-tetrazol-5-ylJ-2,4-diphenyl-pyrlmldin (V, R1 = 4-Et-C8H4, R2 = R3 = Ph)5- | 1- (4-ethyl-phenyl) -1H-tetrazol-5-ylJ-2,4-diphenyl-pyrimidine (V, R 1 = 4-Et-C 8 H 4 , R 2 = R 3 = Ph)

Ausbeute 87%. Farblose Kristalle (aus Ethanol), Schmp. 170-1710C.Yield 87%. Colorless crystals (from ethanol), mp. 170-171 0 C.

5-[1-(4-Methoxy-phenyl)-1 H-tetrazol-5-yl)-2,4-diphenyl-pyrlmidin (V, R1 = 4-MeO-C8H4, R2 = R3 = Ph)5- [1- (4-Methoxy-phenyl) -1H-tetrazol-5-yl) -2,4-diphenyl-pyrimidine (V, R 1 = 4-MeO-C 8 H 4 , R 2 = R 3 = Ph)

Ausbeute 83%. Farblose Kristalle (aus Ethanol), Schmp. 144-1450C.Yield 83%. Colorless crystals (from ethanol), mp 144-145 0 C.

5-[1-(4-Fluor-phenyl)-1 H-tetrazol-5-yl)-2,4-diphenyl-pyrimidin (V, R1 = 4-F-C8H4, R2 = R3 = Ph)5- [1- (4-Fluoro-phenyl) -1H-tetrazol-5-yl) -2,4-diphenyl-pyrimidine (V, R 1 = 4-FC 8 H 4 , R 2 = R 3 = Ph )

Ausbeute 85%. Farblose Nadeln (aus Acetonitril), Schmp. 154-1550C.Yield 85%. Colorless needles (from acetonitrile), mp. 154-155 0 C.

FormeIseiteFormeIseite

H3CH 3 C

H3CH 3 C

N-CH=CHN-CH = CH

+ R2COX+ R 2 COX

-HX-HX

H3C,H 3 C,

H3CH 3 C

COR2 N-CH=CCOR 2 N-CH = C

,1,1

+ r3-C*+ r3-C *

IVIV

NH NH· -(CH3J2NH, -H2ONH NH · - (CH 3 J 2 NH, -H 2 O

R1 R 1

ρ i1· Π ι- 7 4ρ i 1 · Π ι- 7 4

Claims (1)

Verfahren zur Herstellung tetrazolylsubstituierter Pyrimidinderivate der allgemeinen Formel V, in der R1 einen Arylrest, R2 einen Alkyl- oder Arylrest und R3 eine Aminogruppe, Wasserstoff, einen Alkyl- oder einen Arylrest bedeuten, gekennzeichnet dadurch, daß man 1-substituierte 5-(2-Dimethylaminovinyl)-1 H-tetrazole der Formel I, in der R1 einen Arylrest darstellt, in Lösungsmitteln wie Acetonitril oder Benzen.mit Carbonsäurehalogeniden der Formel II, in der R2 einen Alkyl- oder Arylrest und X ein Halogenatom, vorzugsweise Chlor, bedeuten, in Gegenwart äquimolarer Mengen einer Hilfsbase wie Pyridin oder Triethylamin bei Temperaturen bis zum Siedepunkt des Reaktionsgemisches umsetzt und die hierbei gebildeten 1-arylsubstituierten 5-(1-Acyl-2-dimethylamino-vinyl)-1H-tetrazole III mit Guanidin (Formel IV, R3 = NH2) oderCarbonsäureamidinen (Formel IV, R3 = H, Alkyl oder Aryl) in siedender alkoholischer (z.B. methanolischer oder ethanolischer) Lösung in Gegenwart eines basischen Kondensationsmittels, z. B. Natriummethanolat oder Natriumethanolat, zur Reaktion bringt.A process for the preparation of tetrazolyl-substituted pyrimidine derivatives of the general formula V in which R 1 is an aryl radical, R 2 is an alkyl or aryl radical and R 3 is an amino group, hydrogen, an alkyl radical or an aryl radical, characterized in that 1-substituted-5- (2-Dimethylaminovinyl) -1H-tetrazoles of the formula I, in which R 1 represents an aryl radical, in solvents such as acetonitrile or benzene mit Carbonsäurehalogeniden of formula II, in which R 2 is an alkyl or aryl radical and X is a halogen atom, preferably Chlorine, in the presence of equimolar amounts of an auxiliary base such as pyridine or triethylamine at temperatures up to the boiling point of the reaction mixture and the resulting formed 1-arylsubstituierten 5- (1-acyl-2-dimethylamino-vinyl) -1H-tetrazoles III with guanidine ( Formula IV, R 3 = NH 2 ) or Carbonsäureamidinen (formula IV, R 3 = H, alkyl or aryl) in boiling alcoholic (eg methanolic or ethanolic) solution in the presence of a basic en condensation agent, for. As sodium methoxide or sodium ethoxide, brings to the reaction. Hierzu 1 Seite FormelnFor this 1 page formulas Anwendungsgebiet der ErfindungField of application of the invention Die Erfindung betrifft ein Verfahren zur Herstellung tetrazolylsubstituierter Pyrimidinderivate der allgemeinen Formel V, in der R1 einen Arylrest, R2 einen Alkyl- oder Arylrest und R3 eine Aminogruppe, Wasserstoff, einen Alkyl- oder einen Arylrest bedeuten. Heterocyclen dieses Typs sind als Zwischenprodukte zur Synthese biologisch aktiver Verbindungen von Interesse.The invention relates to a process for the preparation of tetrazolyl-substituted pyrimidine derivatives of the general formula V in which R 1 is an aryl radical, R 2 is an alkyl or aryl radical and R 3 is an amino group, hydrogen, an alkyl radical or an aryl radical. Heterocycles of this type are of interest as intermediates for the synthesis of biologically active compounds. Charakteristik des bekannten Standes der TechnikCharacteristic of the known state of the art Tetrazolylsubstituierte Pyrimidinderivate der Formel V sind bisher nicht bekannt (vgl. F. R. BENSON, Chem. Rev. 41 [1947] 1; F.R.BENSON in „Heterocyclic Compounds" [Hrsg. R.C. Elderfieldj, Bd. 8, S.1, Wiley, New York, 1967; R. N. BUTLER, Adv. Heterocycl. Chem. 21 [1977) 324; R. N. BUTLER in „Comprehensive Heterocyclic Chemistry" [Hrsg. A. R. Katritzky und C. W. Rees), Bd. 5, Teil 4 A, S. 791, Pergamon Press, Oxford, 1984).
Für andere Tetrazoly!pyrimidine wurden In der Literatur folgende Herstellungsverfahren beschrieben:
Tetrazolyl-substituted pyrimidine derivatives of the formula V are hitherto unknown (see FR BENSON, Chem. Rev. 41 [1947] 1; FRBENSON in "Heterocyclic Compounds" [Ed. RC Elderfieldj, Vol. 8, p.1, Wiley, New York, Vol. RN BUTLER, Adv. Heterocycl Chem 21 [1977] 324; RN BUTLER in "Comprehensive Heterocyclic Chemistry" [Hrsg. AR Katritzky and CW Rees), Vol. 5, Part 4 A, p. 791, Pergamon Press, Oxford, 1984).
For other tetrazolypyrimidines, the following production methods have been described in the literature:
a) Umsetzung von Cyanopyrimidinen (bzw. Cyanopyrimidonen) mit Natrium- oder Ammoniumazid zu Pyrimidinderivaten mit N-unsubstituiertem 1 H-Tetrazol-5-yl-Rest (z. B. J. P. HOROWITZ und A. J.TOMSON, J. Org. Chem. 26 (1961 ] 3392; D. H. KIM und A.A. SANTILLI, US 3816423, C. A. 81 [1974] 120687; P.T.JUBYundR.A. PARTYKA, DE 2705609,C. A. 87 [1977) P.T. JUBY, T.W.HUDYMA, M.BROWN, J.M.ESSERY und R.A.PARTYKA, J.Med.Chem. 25 [1982] 1146; Fujisawa Pharmaceutical Co., Ltd., JP 57176981, C. A. 98 [1983] 143453; Y. HONMA, Y. SEKINE,T. HASHIYAMA, M.TAKEDA, Y.ONO und K.TSUZURAHARA, Chem. Pharm. Bull.30 [1982]4314; K.KOSEGI,M.SAWADAundT.ICHIKAWA, JP6191184,CA. 105[1986] 208920; W.RIED und S. ABOUL-FETOUH, Chem.-Ztg. 112 [1988] 135);a) reaction of cyanopyrimidines (or cyanopyrimidones) with sodium or ammonium azide to pyrimidine derivatives with N-unsubstituted 1H-tetrazol-5-yl radical (for example, J. P. Horowitz and AJTOMSON, J. Org. Chem. 26 (1961) 3392; DH KIM and AA SANTILLI, US 3816423, CA 81 [1974] 120687; PTJUBY and R. A. PARTYKA, DE 2705609, CA 87 [1977] PT JUBY, TWHUDYMA, M.BROWN, JMESSERY and RAPARTYKA, J M.M.Chem 25 (1982) 1146, Fujisawa Pharmaceutical Co., Ltd., JP 57176981, CA 98 [1983] 143453, Y. HONMA, Y. SEKINE, T.HASHIYAMA, M.TAKEDA, Y.ONO and K.K. .TSUZURAHARA, Chem. Pharm. Bull. 30 [1982] 4314; K. KOSEGI, M.SAWADA and T.ICHIKAWA, JP6191184, CA.105 [1986] 208920; W.RIED and S. ABOUL-FETOUH, Chem.-Ztg. 112 [1988] 135); b) Einführung eines N-verkntipften Tetrazolylrestes durch Substitution geeigneter Pyrimidinderivate (z.B. B.K.SNELL, R.S.ELIAS und P. F. H. FREEMAN, S.African 6701373, CA. 71 [1969] 91517; A. KÖNNECKE, R.DÖRRE und E.LIPPMANN, Tetrahedron Lett. 1978,2071);b) Introduction of an N-linked tetrazolyl radical by substitution of suitable pyrimidine derivatives (eg BKSNELL, RSELIAS and PFH FREEMAN, S.African 6701373, CA 71 [1969] 91517, A. KÖNNECKE, R.DÖRE and E. LIPPMANN, Tetrahedron Lett 1978,2071); c) Umsetzung von N-Pyrimidyl-benzamiden mit PCI5 und Überführung der gebildeten Benzimidchloride mittels HN3 in (5-Aryl-1H-tetrazol-1-yl)-pyrimidinderivate (K. KAMALA, P. J.RAO und K.K.REDDY, Bull. Chem. Soc. Jpn. 61 [1988] 3791).c) Reaction of N-pyrimidylbenzamides with PCI 5 and conversion of the benzimidchlorides formed by means of HN 3 into (5-aryl-1H-tetrazol-1-yl) -pyrimidine derivatives (K. KAMALA, PJRAO and KKREDDY, Bull. Chem. Soc Jpn. 61 [1988] 3791). Aufgrund ihres andersartigen Substitutions- und Verknüpfungsmusters sind jedoch Tetrazolylpyrimidine der Formel V nach keinem der unter a)-c) genannten Verfahren herstellbar. Ein bekanntes Prinzip zum Aufbau von Pyrimidinringen besteht in der Umsetzung von Guanidin oder Amidinen mit Enaminoketonen der allgemeinen Struktur R2N-CH=CR'-COR" (vgl. H. BREDERECK, F. EFFENBERGER und H. BOTSCH, Chem. Ber. 97 [1964] 3397; B. GRAFFE, M.-C.SACQUET, M.-C.BELLASSOUED-FARGEAU und P. MAITTE, J. Heterocycl. Chem. 23 [1986] 1753). Für die Synthese, von Tetrazolylpyrimidinen der Formel V wären nach dieser Methode Enaminoketone erforderlich, in denen R' einen 1-AryM H-letrazol-5-yl-Rest darstellt; tetrazolylsubstituierte Enaminoketone dieses Typs sind bisher unbekannt.However, tetrazolylpyrimidines of the formula V can not be prepared by any of the processes mentioned under a) -c) because of their different substitution and linking pattern. A known principle for the construction of pyrimidine rings is the reaction of guanidine or amidines with enaminoketones of the general structure R 2 N-CH = CR'-COR "(compare H. BREDERECK, F. EFFENBERGER and H. BOTSCH, Chem. 97 [1964] 3397; B. GRAFFE, M.-C.SACQUET, M.-C.BELLASSOUED-FARGEAU and P. MAITTE, J. Heterocycl Chem., 23, 1853 (1986), 1753.) For the synthesis of tetrazolylpyrimidines of the Formula V would require enaminoketones by this method in which R 'represents a 1-AryM H-letrazol-5-yl residue; tetrazolyl-substituted enaminoketones of this type are heretofore unknown. Ziel der ErfindungObject of the invention Die Erfindung hat ein Verfahren zum Ziel, mit dem tetrazolylsubätitulerte Pyrimidinderivate der Formel V in einfacher Weise aus leicht zugänglichen Ausgangsstoffen hergestellt werden können.The invention has for its object a method by which tetrazolyl-substituted pyrimidine derivatives of the formula V can be prepared in a simple manner from readily available starting materials. Darlegung des Wesens der ErfindungExplanation of the essence of the invention Der Erfindung liegt die Aufgabe zugrunde, Tetrazolylpyrimidine der Formel V, in der R1 einen Arylrest, R2 einen Alkyl- oder Arylrest und R3 eine Aminogruppe, Wasserstoff, einen Alkyl- oder einen Arylrest bedeuten, aus geeigneten 1,5-disubstituierten Tetrazolen herzustellen. Die Aufgabe wird erfindungsgemäß dadurch gelöst, daß man 1-substituierte 5-(2-Dimethylamino-vinyl)· 1 H-tetrazole der Formel I, In der R1 einen Arylrest darstellt, in Lösungsmitteln wie Acetonitril oder Benzen mit Carbonsäurehalogeniden der Formel II, in der R2 einen Alkyl- oder Arylrest und X ein Halogenatom, vorzugsweise Chlor,The invention is based on the object tetrazolylpyrimidines of the formula V in which R 1 is an aryl radical, R 2 is an alkyl or aryl radical and R 3 is an amino group, hydrogen, an alkyl or an aryl radical, from suitable 1,5-disubstituted tetrazoles manufacture. The object is achieved according to the invention by reacting 1-substituted 5- (2-dimethylamino-vinyl) .1H-tetrazoles of the formula I in which R 1 is an aryl radical in solvents such as acetonitrile or benzene with carbonyl halides of the formula II, in the R 2 is an alkyl or aryl radical and X is a halogen atom, preferably chlorine,
DD34061090A 1990-05-14 1990-05-14 PROCESS FOR PREPARING TETRAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES DD294255A5 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DD34061090A DD294255A5 (en) 1990-05-14 1990-05-14 PROCESS FOR PREPARING TETRAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DD34061090A DD294255A5 (en) 1990-05-14 1990-05-14 PROCESS FOR PREPARING TETRAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
DD294255A5 true DD294255A5 (en) 1991-09-26

Family

ID=5618453

Family Applications (1)

Application Number Title Priority Date Filing Date
DD34061090A DD294255A5 (en) 1990-05-14 1990-05-14 PROCESS FOR PREPARING TETRAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES

Country Status (1)

Country Link
DD (1) DD294255A5 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035639A1 (en) * 2001-10-22 2003-05-01 Eisai Co., Ltd. Pyrimidine compound and medicinal composition thereof
WO2009007187A1 (en) * 2007-07-09 2009-01-15 Basf Se Substituted 5-hetarylpyrimidines
US8470812B2 (en) 2009-12-30 2013-06-25 Arqule, Inc. Substituted benzo-pyrimido-tetrazolo-diazepine compounds
US9126973B2 (en) 2008-09-22 2015-09-08 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
CN107778262A (en) * 2016-08-24 2018-03-09 尹玉新 1,5 disubstituted tetrazole compounds and its preparation method and application

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035639A1 (en) * 2001-10-22 2003-05-01 Eisai Co., Ltd. Pyrimidine compound and medicinal composition thereof
US7396836B2 (en) 2001-10-22 2008-07-08 Eisai R&D Management Co., Ltd. Pyrimidine compound and medicinal composition thereof
WO2009007187A1 (en) * 2007-07-09 2009-01-15 Basf Se Substituted 5-hetarylpyrimidines
US9126973B2 (en) 2008-09-22 2015-09-08 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US8470812B2 (en) 2009-12-30 2013-06-25 Arqule, Inc. Substituted benzo-pyrimido-tetrazolo-diazepine compounds
CN107778262A (en) * 2016-08-24 2018-03-09 尹玉新 1,5 disubstituted tetrazole compounds and its preparation method and application

Similar Documents

Publication Publication Date Title
DE69603240T2 (en) NEW DEAZAPORE DERIVATIVES; A NEW CLASS OF CRF1-SPECIFIC LIGANDS
DE60319269T2 (en) Pharmaceutical Use of 2-Substituted 4-Heteroaryl Pyrimidine
DE69208263T2 (en) SUBSTITUTED AMINOPYRIMIDINE AS ANGIOTENSIN II ANTAGONISTS
DE69013112T2 (en) PYRIMIDINE DERIVATIVES.
EP1418176B1 (en) Pyrazole derivates, their preparation and their use in drugs
DE69430988T2 (en) PYRAZOLOTRIAZINE WITH INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR INHIBITOR EFFECT
DE69410121T2 (en) DIHYDRO PYRAZOLOPYRROLE
SE457081B (en) 1,2-DIAMINOCYCLOBUTAN-3,4-DIONES, PROCEDURES FOR PREPARING THESE, INTERMEDIATE AND A PHARMACEUTICAL COMPOSITION
DE60220771T2 (en) INHIBITORS OF CYCLINE-DEPENDENT KINASES AS AGENTS AGAINST CANCER
DE2147794A1 (en) New triazoles and preparations containing them
AT503591A2 (en) ADENOSINE A3 RECEPTOR MODULATORS
CH660484A5 (en) 4 - ((2,5-PYRROLIDINDION-1-YL) ALKYL) PIPERAZINE COMPOUNDS SUBSTITUTED IN 1-POSITION BY A HETEROCYCLIC REST.
DE3141063A1 (en) NEW IMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
CH651300A5 (en) HETEROCYCLICALLY SUBSTITUTED AMINOPROPENNITRILE.
DD155520A5 (en) PROCESS FOR THE PREPARATION OF CEPHALOSPORIN DERIVATIVES
EP0122580A1 (en) Pyrimidine derivatives, their preparation and pharmaceutical compositions
Lumma Jr et al. Inhibitors of gastric acid secretion: 3, 4-diamino-1, 2, 5-thiadiazole 1-oxides and 1, 1-dioxides as urea equivalents in a series of histamine H2 receptor antagonists
Hashem et al. Synthesis and reactions of some 2 (3h) and 2 (5h) furanone derivatives: a comparative study
DE1946315A1 (en) New heterocyclic compounds
DE69330593T2 (en) Heterocyclic compounds with angiotensin II antagonistic activity and their application
DD202552A5 (en) HETEROCYCLIC DERIVATIVES
DE3618724C2 (en) N- [3- (Nitro) -quinol-4-yl] carboxamidinamides, process for their preparation and medicaments containing these compounds
DE1909110A1 (en) Process for the preparation of new heterocyclic compounds
DE68911944T2 (en) Cardiotonic alkanoyl and aroyloxazoles.
DE2109577A1 (en) Antimicrobial Nitrofuran Derivatives and Process for the Production of the Same

Legal Events

Date Code Title Description
NPI Change in the person, name or address of the patentee (addendum to changes before extension act)
ENJ Ceased due to non-payment of renewal fee